192 related articles for article (PubMed ID: 30747998)
1. Cyclooxygenase-2 in gastrointestinal malignancies.
Nagaraju GP; El-Rayes BF
Cancer; 2019 Apr; 125(8):1221-1227. PubMed ID: 30747998
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms.
Wu WK; Sung JJ; Lee CW; Yu J; Cho CH
Cancer Lett; 2010 Sep; 295(1):7-16. PubMed ID: 20381235
[TBL] [Abstract][Full Text] [Related]
3. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M; Coveñas R
Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
[TBL] [Abstract][Full Text] [Related]
4. Aquaporins: Their role in gastrointestinal malignancies.
Nagaraju GP; Basha R; Rajitha B; Alese OB; Alam A; Pattnaik S; El-Rayes B
Cancer Lett; 2016 Apr; 373(1):12-18. PubMed ID: 26780474
[TBL] [Abstract][Full Text] [Related]
5. COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention.
Cathcart MC; O'Byrne KJ; Reynolds JV; O'Sullivan J; Pidgeon GP
Biochim Biophys Acta; 2012 Jan; 1825(1):49-63. PubMed ID: 22015819
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors.
Wang R; Guo L; Wang P; Yang W; Lu Y; Huang Z; Tang C
Curr Pharm Des; 2013; 19(1):115-25. PubMed ID: 22950494
[TBL] [Abstract][Full Text] [Related]
7. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
[TBL] [Abstract][Full Text] [Related]
8. Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma.
Buskens CJ; Ristimäki A; Offerhaus GJ; Richel DJ; van Lanschot JJ
Scand J Gastroenterol Suppl; 2003; (239):87-93. PubMed ID: 14743889
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract.
Konturek PC; Kania J; Burnat G; Hahn EG; Konturek SJ
J Physiol Pharmacol; 2005 Sep; 56 Suppl 5():57-73. PubMed ID: 16247189
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2: a novel target for cancer chemotherapy?
Dempke W; Rie C; Grothey A; Schmoll HJ
J Cancer Res Clin Oncol; 2001 Jul; 127(7):411-7. PubMed ID: 11469677
[TBL] [Abstract][Full Text] [Related]
11. MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside.
Avan A; Maftouh M; Funel N; Ghayour-Mobarhan M; Boggi U; Peters GJ; Giovannetti E
Curr Med Chem; 2014; 21(8):975-89. PubMed ID: 23992325
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenases in hepatocellular carcinoma.
Cervello M; Montalto G
World J Gastroenterol; 2006 Aug; 12(32):5113-21. PubMed ID: 16937518
[TBL] [Abstract][Full Text] [Related]
13. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 (COX-2)--a therapeutic target in liver cancer?
Breinig M; Schirmacher P; Kern MA
Curr Pharm Des; 2007; 13(32):3305-15. PubMed ID: 18045183
[TBL] [Abstract][Full Text] [Related]
15. Targeted molecular ablation of cancer stem cells for curing gastrointestinal cancers.
Kim YS; Lee HJ; Park JM; Han YM; Kangwan N; Oh JY; Lee DY; Hahm KB
Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):1059-1070. PubMed ID: 28707966
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in upper gastrointestinal malignancies.
Azzariti A; Silvestris N
Curr Med Chem; 2014; 21(8):947. PubMed ID: 23992326
[No Abstract] [Full Text] [Related]
17. Cyclooxygenase-2 in cancer: A review.
Hashemi Goradel N; Najafi M; Salehi E; Farhood B; Mortezaee K
J Cell Physiol; 2019 May; 234(5):5683-5699. PubMed ID: 30341914
[TBL] [Abstract][Full Text] [Related]
18. Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: targets for treatment.
Rengifo-Cam W; Singh P
Curr Pharm Des; 2004; 10(19):2345-58. PubMed ID: 15279613
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Jiménez P; García A; Santander S; Piazuelo E
Curr Pharm Des; 2007; 13(22):2261-73. PubMed ID: 17691999
[TBL] [Abstract][Full Text] [Related]
20. Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression.
Yi C; Wang Y; Zhang C; Xuan Y; Zhao S; Liu T; Li W; Liao Y; Feng X; Hao J; Gao Y; Yu W; Chen Y; Zhang C; Guo W; Tang B; Deng W
Cancer Lett; 2016 Oct; 381(1):1-13. PubMed ID: 27450326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
